New obesity drug KAI-9531 takes on semaglutide in major trial

NCT ID NCT07284979

First seen Jan 02, 2026 · Last updated Apr 24, 2026 · Updated 14 times

Summary

This study tests a new weekly injection called KAI-9531 to help people with obesity lose weight. About 1,200 adults with a BMI of 35 or higher who do not have diabetes will receive either KAI-9531, semaglutide (a current weight-loss drug), or a placebo. The main goal is to see how much weight they lose over 76 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kailera Clinical Site

    RECRUITING

    Glendale, Arizona, 85308, United States

  • Kailera Clinical Site

    RECRUITING

    Phoenix, Arizona, 85012, United States

  • Kailera Clinical Site

    RECRUITING

    Little Rock, Arkansas, 72205, United States

  • Kailera Clinical Site

    RECRUITING

    Northridge, California, 91325, United States

  • Kailera Clinical Site

    RECRUITING

    Oceanside, California, 92058, United States

  • Kailera Clinical Site

    RECRUITING

    Hamden, Connecticut, 06517, United States

  • Kailera Clinical Site

    RECRUITING

    Stamford, Connecticut, 06905, United States

  • Kailera Clinical Site

    RECRUITING

    Orange City, Florida, 32763, United States

  • Kailera Clinical Site

    RECRUITING

    Albany, Georgia, 31707, United States

  • Kailera Clinical Site

    RECRUITING

    Chicago, Illinois, 60640, United States

  • Kailera Clinical Site

    RECRUITING

    Newton, Kansas, 67114, United States

  • Kailera Clinical Site

    RECRUITING

    Shreveport, Louisiana, 71105, United States

  • Kailera Clinical Site

    RECRUITING

    Farmington Hills, Michigan, 48334, United States

  • Kailera Clinical Site

    RECRUITING

    Missoula, Montana, 59804, United States

  • Kailera Clinical Site

    RECRUITING

    Las Vegas, Nevada, 89148, United States

  • Kailera Clinical Site

    RECRUITING

    Albany, New York, 12203, United States

  • Kailera Clinical Site

    RECRUITING

    Morehead City, North Carolina, 28557, United States

  • Kailera Clinical Site

    RECRUITING

    Norman, Oklahoma, 73069, United States

  • Kailera Clinical Site

    RECRUITING

    East Greenwich, Rhode Island, 02818, United States

  • Kailera Clinical Site

    RECRUITING

    North Charleston, South Carolina, 29405, United States

  • Kailera Clinical Site

    RECRUITING

    Spartanburg, South Carolina, 29303, United States

  • Kailera Clinical Site

    RECRUITING

    Brownsville, Texas, 78526, United States

  • Kailera Clinical Site

    RECRUITING

    San Antonio, Texas, 78229, United States

  • Kailera Clinical Site

    RECRUITING

    Manassas, Virginia, 20110, United States

  • Kailera Clinical Site

    RECRUITING

    Richmond, Virginia, 23236, United States

Conditions

Explore the condition pages connected to this study.